SRPT:NSD-Sarepta Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 124.53

Change

0.00 (0.00)%

Market Cap

USD 11.88B

Volume

0.77M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.95B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 10.84 % 0.00 %

N/A

USD 0.24B
MSGR 6.12 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.11 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 4.31 % 0.00 %

N/A

CAD 5.07M
IDNA iShares Genomics Immunolo.. 4.31 % 0.00 %

N/A

USD 0.14B
CURG:LSE VanEck Genomics and Healt.. 3.94 % 0.00 %

N/A

USD 7.23M
GN0M:XETRA Global X Genomics & Biote.. 3.82 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.82 % 0.00 %

N/A

USD 6.06M
IBRN iShares Trust - iShares N.. 3.74 % 0.00 %

N/A

USD 3.84M
BIOT:SW L&G Pharma Breakthrough U.. 3.00 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.69 % 0.00 %

N/A

USD 0.04B
WDNA:LSE WisdomTree BioRevolution .. 1.73 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 1.71 % 1.14 %

N/A

USD 0.94B
PAMC Pacer Lunt MidCap Multi-F.. 1.40 % 0.00 %

N/A

USD 0.06B
THNZ:XETRA L&G Global Thematic ESG E.. 0.80 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.77 % 0.00 %

N/A

N/A
AGED:SW iShares Ageing Population.. 0.68 % 0.00 %

N/A

N/A
USSMC:SW UBS (Irl) ETF plc - MSCI .. 0.60 % 0.00 %

N/A

N/A
CSY8:F Credit Suisse Index Fund .. 0.50 % 0.00 %

N/A

USD 0.55B
CSY8:XETRA UBS (Irl) ETF plc - MSCI .. 0.50 % 0.00 %

N/A

USD 0.55B
H41G:XETRA HSBC MSCI World Small Cap.. 0.39 % 0.00 %

N/A

N/A
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 0.00 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 674.84% 77% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 674.84% 77% C+ 90% A-
Trailing 12 Months  
Capital Gain 516.38% 75% C 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 516.38% 75% C 89% A-
Trailing 5 Years  
Capital Gain 876.32% 81% B- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 876.32% 81% B- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 10.82% N/A N/A 68% D+
Dividend Return 10.82% N/A N/A 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.45% N/A N/A 29% F
Risk Adjusted Return 17.90% N/A N/A 53% F
Market Capitalization 11.88B 98% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.